Pharmaceutical Chemicals Heparin Sodium Enoxaparin Sodium for Anticoagulation with EP CAS#679809-58-6

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: CAS#679809-58-6
• Transport Package: 25kg/Drum
• Specification: 42*42*52
• Trademark: Hanways
• Origin: China
• HS Code: 2932209090
• Production Capacity: 2000 Kilogram/Month

Product Description

Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Product Name	ENOXAPARIN SODIUM
Synonyms	ENOXAPARIN SODIUM, EP STANDARD;Lovenox;Lovenox (preservative free);Unii-8nz41mik1o;Clexane;Enoxil;Klexane;
MOQ	1kg
CAS	679809-58-6
Appearance	White
Molecular Formula	C57H82N4Na4O53S3
Molecular Weight	00
Assay	>99%
Application	For research purpose only
Packing	25kg/drum
Storage	Store in a well-closed,light-resistant container
Remarks	NA
Custom synthesis	Available

Indication:

Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction. 

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.